Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16740713rdf:typepubmed:Citationlld:pubmed
pubmed-article:16740713lifeskim:mentionsumls-concept:C1519346lld:lifeskim
pubmed-article:16740713lifeskim:mentionsumls-concept:C0032405lld:lifeskim
pubmed-article:16740713lifeskim:mentionsumls-concept:C0215848lld:lifeskim
pubmed-article:16740713lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:16740713lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:16740713lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:16740713lifeskim:mentionsumls-concept:C0332257lld:lifeskim
pubmed-article:16740713lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:16740713pubmed:issue11lld:pubmed
pubmed-article:16740713pubmed:dateCreated2006-6-2lld:pubmed
pubmed-article:16740713pubmed:abstractTextPoly(ADP-ribose) polymerase (PARP)-1, an enzyme that catalyzes the attachment of ADP ribose to target proteins, acts as a component of enhancer/promoter regulatory complexes. In the present study, we show that pharmacologic inhibition of PARP-1 with 3,4-dihydro-5-[4-(1-piperidinyl)butoxyl]-1(2H)-isoquinolinone (DPQ) results in a strong delay in tumor formation and in a dramatic reduction in tumor size and multiplicity during 7,12-dimethylbenz(a)anthracene plus 12-O-tetradecanoylphorbol-13-acetate-induced skin carcinogenesis. This observation was parallel with a reduction in the skin inflammatory infiltrate in DPQ-treated mice and tumor vasculogenesis. Inhibition of PARP also affected activator protein-1 (AP-1) activation but not nuclear factor-kappaB (NF-kappaB). Using cDNA expression array analysis, a substantial difference in key tumor-related gene expression was found between chemically induced mice treated or not with PARP inhibitor and also between wild-type and parp-1 knockout mice. Most important differences were found in gene expression for Nfkbiz, S100a9, Hif-1alpha, and other genes involved in carcinogenesis and inflammation. These results were corroborated by real-time PCR. Moreover, the transcriptional activity of hypoxia-inducible factor-1alpha (HIF-1alpha) was compromised by PARP inhibition or in PARP-1-deficient cells, as measured by gene reporter assays and the expression of key target genes for HIF-1alpha. Tumor vasculature was also strongly inhibited in PARP-1-deficient mice and by DPQ. In summary, this study shows that inhibition of PARP on itself is able to control tumor growth, and PARP inhibition or genetic deletion of PARP-1 prevents from tumor promotion through their ability to cooperate with the activation AP-1, NF-kappaB, and HIF-1alpha.lld:pubmed
pubmed-article:16740713pubmed:languageenglld:pubmed
pubmed-article:16740713pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16740713pubmed:citationSubsetIMlld:pubmed
pubmed-article:16740713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16740713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16740713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16740713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16740713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16740713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16740713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16740713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16740713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16740713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16740713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16740713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16740713pubmed:statusMEDLINElld:pubmed
pubmed-article:16740713pubmed:monthJunlld:pubmed
pubmed-article:16740713pubmed:issn0008-5472lld:pubmed
pubmed-article:16740713pubmed:authorpubmed-author:VilluendasRaq...lld:pubmed
pubmed-article:16740713pubmed:authorpubmed-author:OliverF...lld:pubmed
pubmed-article:16740713pubmed:authorpubmed-author:Ruiz de...lld:pubmed
pubmed-article:16740713pubmed:authorpubmed-author:Aguilar-Quesa...lld:pubmed
pubmed-article:16740713pubmed:authorpubmed-author:PirisMiguel...lld:pubmed
pubmed-article:16740713pubmed:authorpubmed-author:Martin-OlivaD...lld:pubmed
pubmed-article:16740713pubmed:authorpubmed-author:O'valleFranci...lld:pubmed
pubmed-article:16740713pubmed:authorpubmed-author:Muñoz-GámezJo...lld:pubmed
pubmed-article:16740713pubmed:authorpubmed-author:Martínez-Rome...lld:pubmed
pubmed-article:16740713pubmed:authorpubmed-author:García Del...lld:pubmed
pubmed-article:16740713pubmed:issnTypePrintlld:pubmed
pubmed-article:16740713pubmed:day1lld:pubmed
pubmed-article:16740713pubmed:volume66lld:pubmed
pubmed-article:16740713pubmed:ownerNLMlld:pubmed
pubmed-article:16740713pubmed:authorsCompleteYlld:pubmed
pubmed-article:16740713pubmed:pagination5744-56lld:pubmed
pubmed-article:16740713pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16740713pubmed:meshHeadingpubmed-meshheading:16740713...lld:pubmed
pubmed-article:16740713pubmed:meshHeadingpubmed-meshheading:16740713...lld:pubmed
pubmed-article:16740713pubmed:meshHeadingpubmed-meshheading:16740713...lld:pubmed
pubmed-article:16740713pubmed:meshHeadingpubmed-meshheading:16740713...lld:pubmed
pubmed-article:16740713pubmed:meshHeadingpubmed-meshheading:16740713...lld:pubmed
pubmed-article:16740713pubmed:meshHeadingpubmed-meshheading:16740713...lld:pubmed
pubmed-article:16740713pubmed:meshHeadingpubmed-meshheading:16740713...lld:pubmed
pubmed-article:16740713pubmed:meshHeadingpubmed-meshheading:16740713...lld:pubmed
pubmed-article:16740713pubmed:meshHeadingpubmed-meshheading:16740713...lld:pubmed
pubmed-article:16740713pubmed:meshHeadingpubmed-meshheading:16740713...lld:pubmed
pubmed-article:16740713pubmed:meshHeadingpubmed-meshheading:16740713...lld:pubmed
pubmed-article:16740713pubmed:meshHeadingpubmed-meshheading:16740713...lld:pubmed
pubmed-article:16740713pubmed:meshHeadingpubmed-meshheading:16740713...lld:pubmed
pubmed-article:16740713pubmed:meshHeadingpubmed-meshheading:16740713...lld:pubmed
pubmed-article:16740713pubmed:meshHeadingpubmed-meshheading:16740713...lld:pubmed
pubmed-article:16740713pubmed:meshHeadingpubmed-meshheading:16740713...lld:pubmed
pubmed-article:16740713pubmed:year2006lld:pubmed
pubmed-article:16740713pubmed:articleTitleInhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis.lld:pubmed
pubmed-article:16740713pubmed:affiliationInstitute of Parasitology and Biomedicine, Consejo Superior de Investigaciones Cientificas, Granada, Spain.lld:pubmed
pubmed-article:16740713pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16740713pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16740713lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16740713lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16740713lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16740713lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16740713lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16740713lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16740713lld:pubmed